D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 129 SEK -1.9% Market Closed
Market Cap: 2.1B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Other Receivables
kr11.6m
CAGR 3-Years
10%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Other Receivables
kr27.6m
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Other Receivables
kr47m
CAGR 3-Years
67%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Other Receivables
kr91m
CAGR 3-Years
109%
CAGR 5-Years
62%
CAGR 10-Years
22%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Other Receivables
kr3.4B
CAGR 3-Years
57%
CAGR 5-Years
34%
CAGR 10-Years
35%
BioArctic AB
STO:BIOA B
Other Receivables
kr6.9m
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.1B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
124.21 SEK
Overvaluation 4%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Other Receivables?
Other Receivables
11.6m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Other Receivables amounts to 11.6m SEK.

What is Devyser Diagnostics AB's Other Receivables growth rate?
Other Receivables CAGR 5Y
55%

Over the last year, the Other Receivables growth was 101%. The average annual Other Receivables growth rates for Devyser Diagnostics AB have been 10% over the past three years , 55% over the past five years .

Back to Top